실적분석 2026년 7월 31일

Balchem ($BCPC) Q2 2026 Earnings Analysis — Adjusted EPS and Revenue Both Beat, Modest After-Hours Reaction

Earnings Scorecard

Revenue: $284M (+11.2% YoY, vs. $269M estimate) ✅ Beat

EPS: Adjusted $1.49 (vs. $1.43 estimate) ✅ Beat

Guidance: None provided — confidence in long-term growth reiterated, but no next-quarter or full-year numerical outlook

Stock Reaction: +0.53% after-hours ($163.6) — as of 07-31 20:05 KST

Positives

Growth across all three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products all posted year-over-year revenue gains

Record quarter: Revenue, net income, and adjusted EBITDA all hit all-time quarterly highs

Sharp jump in Animal Nutrition profit: Segment operating income rose roughly 49% YoY

Balchem produces nutritional ingredients for food, dietary supplements, and animal feed, along with specialty gases. Q2 revenue came in at $284 million, up 11.2% year-over-year and above the $269 million the market had expected. Adjusted EPS of $1.49 topped the $1.43 estimate, while GAAP EPS was $1.39.

Human Nutrition & Health revenue was $176.9 million (+10.0%), Animal Nutrition & Health was $64.5 million (+15.0%), and Specialty Products was $40.5 million (+8.9%) — growth across all three reporting segments. The Animal Nutrition segment stood out, with stronger demand in monogastric (swine and poultry) and ruminant markets lifting operating income to $5.2 million, up 48.7% YoY. Consolidated gross margin edged up 0.1 percentage points to 36.5%.

Negatives

Manufacturing cost pressure: Higher input costs across all segments partially offset margin gains

Lower free cash flow: $36.2 million in Q2, down from roughly $40.7 million a year earlier

No numerical guidance: No next-quarter or full-year revenue or earnings outlook provided

Despite a strong quarter, the company said higher manufacturing input costs and operating expenses across all segments partially weighed on profits. Operating expenses rose about $2.8 million YoY, driven by higher compensation-related costs. The effective tax rate also edged up to 22.8% from 21.9% a year earlier.

Free cash flow was $36.2 million — operating cash flow remained solid, but higher capital spending pulled the figure below the prior-year period. The press release also lacked specific guidance for next-quarter or full-year revenue and EPS, leaving the market without hard numbers to gauge how much further upside might be in store.

What Management Said

Management described Q2 as a "very strong quarter," emphasizing healthy growth across all three reporting segments and record consolidated quarterly highs for revenue, net income, and adjusted EBITDA. First-half results were framed as a continuation of the company's established growth momentum, with management saying it is executing on strategic growth initiatives and maintaining confidence in long-term growth.

No specific numbers were offered for next-quarter or full-year outlook. Instead, the tone emphasized capital allocation and growth-investment capacity, including a credit-facility expansion (from $550M to $650M, maturing in 2031) and roughly $29 million in share repurchases during Q2. From the market's perspective, the read-through is a solid print paired with limited forward visibility.

Market Reaction and Key Things to Watch

Even with adjusted EPS and revenue both beating estimates and balanced growth across the three segments, the after-hours stock reaction was muted. A plausible interpretation is that strong earnings expectations were already largely priced in, and the absence of next-quarter or full-year numerical guidance left investors without a clear "further upgrade" catalyst. Cost inflation and softer free cash flow also temper pure optimism.

Watch whether revenue and operating-income growth across the three segments continues into the next quarter.

Monitor how much manufacturing input costs and compensation expense pressure gross and operating margins.

Key points to track: whether free cash flow recovers as capex and working-capital changes normalize, and whether the pace of share repurchases is sustained.